rs61734190

Variant summary

Our verdict is Benign. The variant received -8 ACMG points: 0P and 8B. BA1

This summary comes from the ClinGen Evidence Repository: The allele frequency of the c.313T>C p.(Leu105=) variant in UBE3A (NM_130838.2) is 7.5% in African/African-American sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). In summary, the c.313T>C p.(Leu105=) variant in UBE3A is classified as Benign based on the ACMG/AMP criteria (BA1). LINK:https://erepo.genome.network/evrepo/ui/classification/CA149410/MONDO:0007113/016

Frequency

Genomes: 𝑓 0.021 ( 120 hom., cov: 32)
Exomes 𝑓: 0.0021 ( 100 hom. )

Consequence

UBE3A
NM_130839.5 synonymous

Scores

2

Clinical Significance

Benign reviewed by expert panel U:1B:7

Conservation

PhyloP100: 3.35

Publications

3 publications found
Variant links:
Genes affected
UBE3A (HGNC:12496): (ubiquitin protein ligase E3A) This gene encodes an E3 ubiquitin-protein ligase, part of the ubiquitin protein degradation system. This imprinted gene is maternally expressed in brain and biallelically expressed in other tissues. Maternally inherited deletion of this gene causes Angelman Syndrome, characterized by severe motor and intellectual retardation, ataxia, hypotonia, epilepsy, absence of speech, and characteristic facies. The protein also interacts with the E6 protein of human papillomavirus types 16 and 18, resulting in ubiquitination and proteolysis of tumor protein p53. Alternative splicing of this gene results in three transcript variants encoding three isoforms with different N-termini. Additional transcript variants have been described, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]
SNHG14 (HGNC:37462): (small nucleolar RNA host gene 14) This gene is located within the Prader-Willi critical region and produces a long, spliced paternally-imprinted RNA that initiates within a common upstream promoter region shared by the SNRPN (small nuclear ribonucleoprotein polypeptide N) and SNURF genes. This transcript serves as a host RNA for the small nucleolar RNA, C/D box 115 and 116 clusters. This RNA extends in antisense into the region of the ubiquitin protein ligase E3A gene (UBE3A), and is thought to regulate imprinted expression of UBE3A in the brain. This transcript undergoes extensive alternative splicing, and may initiate and terminate at multiple locations within this genomic region. The full-length structure of all splice forms is not determined. [provided by RefSeq, Mar 2017]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -8 ACMG points.

BA1
For more information check the summary or visit ClinGen Evidence Repository.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_130839.5. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
UBE3A
NM_130839.5
MANE Select
c.373T>Cp.Leu125Leu
synonymous
Exon 6 of 13NP_570854.1
UBE3A
NM_000462.5
c.382T>Cp.Leu128Leu
synonymous
Exon 7 of 14NP_000453.2
UBE3A
NM_001354505.1
c.373T>Cp.Leu125Leu
synonymous
Exon 6 of 13NP_001341434.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
UBE3A
ENST00000648336.2
MANE Select
c.373T>Cp.Leu125Leu
synonymous
Exon 6 of 13ENSP00000497572.2
UBE3A
ENST00000566215.5
TSL:1
c.313T>Cp.Leu105Leu
synonymous
Exon 8 of 15ENSP00000457771.1
SNHG14
ENST00000424333.6
TSL:1
n.5767-46987A>G
intron
N/A

Frequencies

GnomAD3 genomes
AF:
0.0213
AC:
3247
AN:
152146
Hom.:
120
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0737
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00963
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000414
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000191
Gnomad OTH
AF:
0.0167
GnomAD2 exomes
AF:
0.00561
AC:
1380
AN:
245968
AF XY:
0.00423
show subpopulations
Gnomad AFR exome
AF:
0.0762
Gnomad AMR exome
AF:
0.00457
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0000546
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000178
Gnomad OTH exome
AF:
0.00433
GnomAD4 exome
AF:
0.00206
AC:
2999
AN:
1456882
Hom.:
100
Cov.:
32
AF XY:
0.00174
AC XY:
1265
AN XY:
724966
show subpopulations
African (AFR)
AF:
0.0700
AC:
2334
AN:
33348
American (AMR)
AF:
0.00536
AC:
239
AN:
44566
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26094
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39668
South Asian (SAS)
AF:
0.0000581
AC:
5
AN:
86110
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
49640
Middle Eastern (MID)
AF:
0.00278
AC:
16
AN:
5762
European-Non Finnish (NFE)
AF:
0.0000990
AC:
110
AN:
1111392
Other (OTH)
AF:
0.00489
AC:
295
AN:
60302
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.449
Heterozygous variant carriers
0
133
266
399
532
665
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
76
152
228
304
380
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0214
AC:
3251
AN:
152264
Hom.:
120
Cov.:
32
AF XY:
0.0205
AC XY:
1524
AN XY:
74442
show subpopulations
African (AFR)
AF:
0.0736
AC:
3055
AN:
41532
American (AMR)
AF:
0.00962
AC:
147
AN:
15286
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5176
South Asian (SAS)
AF:
0.000207
AC:
1
AN:
4828
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10620
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.000191
AC:
13
AN:
68030
Other (OTH)
AF:
0.0165
AC:
35
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.495
Heterozygous variant carriers
0
144
289
433
578
722
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
38
76
114
152
190
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0113
Hom.:
26
Bravo
AF:
0.0235
Asia WGS
AF:
0.00346
AC:
12
AN:
3478
EpiCase
AF:
0.000164
EpiControl
AF:
0.000178

ClinVar

Significance: Benign
Submissions summary: Uncertain:1Benign:7
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Angelman syndrome Uncertain:1Benign:2
Feb 14, 2014
Baylor Genetics
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

possible diagnosis of Angelman syndrome

Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Jun 30, 2022
ClinGen Rett and Angelman-like Disorders Variant Curation Expert Panel
Significance:Benign
Review Status:reviewed by expert panel
Collection Method:curation

The allele frequency of the c.313T>C p.(Leu105=) variant in UBE3A (NM_130838.2) is 7.5% in African/African-American sub population in gnomAD, which is high enough to be classified as benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BA1). In summary, the c.313T>C p.(Leu105=) variant in UBE3A is classified as Benign based on the ACMG/AMP criteria (BA1).

not specified Benign:3
Feb 08, 2013
Genetic Services Laboratory, University of Chicago
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Mar 13, 2015
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Jun 20, 2016
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.

Inborn genetic diseases Benign:1
Mar 16, 2016
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.

not provided Benign:1
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.59
CADD
Benign
7.0
DANN
Benign
0.74
PhyloP100
3.4
Mutation Taster
=99/1
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.030
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs61734190; hg19: chr15-25616948; API